Post-parandial lipid effects of MK-0518 (raltegaravir) vs low-dose ritonavir (100mg daily) in HIV-negative adults

Trial Profile

Post-parandial lipid effects of MK-0518 (raltegaravir) vs low-dose ritonavir (100mg daily) in HIV-negative adults

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Raltegravir (Primary) ; Ritonavir
  • Indications HIV infections
  • Focus Adverse reactions
  • Acronyms RoaR
  • Most Recent Events

    • 17 Jul 2010 Results have been published in AIDS.
    • 16 Feb 2010 Status changed from not yet recruiting to completed.
    • 16 Feb 2010 Results presented at the 17th Conference on Retroviruses and Opportunistic Infections.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top